ABSTRACT
Rationale Ongoing secondhand tobacco smoke (SHS) exposure is associated with worsened respiratory health, but little is known about the long-term impact decades after exposure ended.
Objective Determine the long-term consequences of SHS exposure on respiratory health.
Methods Population-based, cohort study in subjects ≥50 years old who had >1 year versus ≤1 year of airline occupational SHS-exposure.
Measurements and Main Results Respiratory health was the primary outcome measured by the St. George’s Respiratory Questionnaire (SGRQ). Key secondary outcomes included respiratory symptoms measured by COPD Assessment Test (CAT) and pre-bronchodilator lung function. The study enrolled 183 SHS-exposed and 59 unexposed subjects. SHS-exposed subjects were exposed to airline SHS for 16.1±9.3 years, which ended 27.5±9.4 years prior to enrollment. Prior SHS-exposure was associated with worse respiratory health based on a 6.7-unit increase in SGRQ (95% CI=[2.7, 10.7]; p=0.001) and 3-unit increase in CAT (95% CI=1.4, 4.6]; p<0.001) versus unexposed subjects, but was not associated with airflow obstruction defined by FEV1:FVC<0.7. Clinically-significant respiratory symptoms (CAT≥10) in SHS-exposed never smokers with preserved lung function (FEV1:FVC ≥0.7 and FVC ≥lower limit of normal) were associated with decreased respiratory and non-respiratory quality-of-life, reduced lung function that remained within the normal range, increased comorbidities and inhaled bronchodilator use, higher plasma CRP and SAA-1 and fewer sinonasal basal stem/progenitor cells versus asymptomatic (CAT<10) SHS-exposed subjects.
Conclusion SHS is associated with a phenotype of impaired respiratory health almost 3 decades after exposure ended, consistent with a symptomatic form of COPD with preserved lung function recently described in smokers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grants from the Flight Attendant Medical Research Institute (FAMRI) to RWV, MG and DNF (150001F, CIA203596 and CIA160014), and grants from the National Institutes of Health to MG and RWV (HL129938-03) and MG (CA219893).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Colorado Multiple Institutional Review Board approved the study (COMIRB 14-0556) and all subjects signed informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: None
Study Impact: The study shows that prior secondhand tobacco smoke (SHS) exposure results in symptomatic respiratory disease with a clinical and biologic phenotype that is similar to symptomatic COPD with preserved lung function in smokers. These findings support a role for SHS-exposure in the development of ∼25% of COPD that is not directly cause by smoking, point to airway basal progenitor cell dysfunction as a potential mechanism of disease, and will encourage clinicians to ask patients about current or past exposure to SHS.
Data Availability
De-identified data from this study will be made available to other investigators upon request.
